Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAL-119
- Development stage
- Phase 2
- Lead developer
- Paulex Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PAL-119 is an orally administered, selective small molecule inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) under development by Paulex Bio. DYRK1A acts as a molecular brake on human pancreatic beta cell proliferation by phosphorylating and removing the transcription factor NFAT (nuclear factor of activated T-cells) from the nucleus. By inhibiting DYRK1A, PAL-119 restores NFAT nuclear localization and transcriptional activity, thereby promoting beta cell regeneration, differentiation, and improved insulin production. PAL-119 is being evaluated in Phase 1/2a clinical trials for the treatment of type 1 and type 2 diabetes, aiming to restore endogenous insulin production and potentially offer insulin independence.
02
Targets
DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)
Beyond the preview
Go deeper on PAL-119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAL-119.